These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 31903933)

  • 1. [Developability assessment with case studies highlighting the decision taking].
    Dumas J; Sévérac A; Lemoine C; Huille S; Rak A; Prades C
    Med Sci (Paris); 2019 Dec; 35(12):1171-1174. PubMed ID: 31903933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Developability assessment].
    Dumas J; Huille S; Prades C
    Med Sci (Paris); 2019 Dec; 35(12):1163-1170. PubMed ID: 31903932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [MI-mAbs, pre-industrial demonstrator supported by PIA for the early validation of therapeutic targets using monoclonal antibodies].
    Romagné F
    Med Sci (Paris); 2019 Dec; 35(12):1202-1203. PubMed ID: 31903940
    [No Abstract]   [Full Text] [Related]  

  • 4. [The long path (s) of placing medicines on the market].
    Duguet C
    Med Sci (Paris); 2019 Mar; 35 Hors série n° 1():13-17. PubMed ID: 30943154
    [No Abstract]   [Full Text] [Related]  

  • 5. In vitro and in silico assessment of the developability of a designed monoclonal antibody library.
    Wolf Pérez AM; Sormanni P; Andersen JS; Sakhnini LI; Rodriguez-Leon I; Bjelke JR; Gajhede AJ; De Maria L; Otzen DE; Vendruscolo M; Lorenzen N
    MAbs; 2019; 11(2):388-400. PubMed ID: 30523762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benchmarking biopharmaceutical process development and manufacturing cost contributions to R&D.
    Farid SS; Baron M; Stamatis C; Nie W; Coffman J
    MAbs; 2020; 12(1):1754999. PubMed ID: 32449439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of data integrity on decision making in early lead discovery.
    Beck B; Seeliger D; Kriegl JM
    J Comput Aided Mol Des; 2015 Sep; 29(9):911-21. PubMed ID: 26409840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compound screening: Fresh hunting ground.
    McGilvray A
    Nature; 2016 May; 533(7602):S65-7. PubMed ID: 27167395
    [No Abstract]   [Full Text] [Related]  

  • 9. Developability assessment in pharmaceutical industry: An integrated group approach for selecting developable candidates.
    Saxena V; Panicucci R; Joshi Y; Garad S
    J Pharm Sci; 2009 Jun; 98(6):1962-79. PubMed ID: 18855914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Model-Informed Drug Development: A Regulatory Perspective on Progress.
    Zhu H; Huang SM; Madabushi R; Strauss DG; Wang Y; Zineh I
    Clin Pharmacol Ther; 2019 Jul; 106(1):91-93. PubMed ID: 31162631
    [No Abstract]   [Full Text] [Related]  

  • 11. Emerging technologies for prediction of drug candidate efficacy in the preclinical pipeline.
    Menshykau D
    Drug Discov Today; 2017 Nov; 22(11):1598-1603. PubMed ID: 28545837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk-Based Comparability Assessment for Monoclonal Antibodies During Drug Development: A Clinical Pharmacology Perspective.
    Zhuang Y; Chen D; Sharma A; Xu Z
    AAPS J; 2018 Oct; 20(6):109. PubMed ID: 30324224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NMR screening in fragment-based drug design: a practical guide.
    Kim HY; Wyss DF
    Methods Mol Biol; 2015; 1263():197-208. PubMed ID: 25618347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developability assessment for monoclonal antibody drug candidates: a case study.
    Garripelli VK; Wu Z; Gupta S
    Pharm Dev Technol; 2021 Jan; 26(1):11-20. PubMed ID: 32986499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Open access high throughput drug discovery in the public domain: a Mount Everest in the making.
    Roy A; McDonald PR; Sittampalam S; Chaguturu R
    Curr Pharm Biotechnol; 2010 Nov; 11(7):764-78. PubMed ID: 20809896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are mAbs different?: a comment on Cohen and Wilson.
    Neumann PJ
    MAbs; 2009; 1(1):29-30. PubMed ID: 20046571
    [No Abstract]   [Full Text] [Related]  

  • 17. Preclinical data reproducibility for R&D--the challenge for neuroscience.
    Steckler T
    Psychopharmacology (Berl); 2015 Jan; 232(2):317-20. PubMed ID: 25585680
    [No Abstract]   [Full Text] [Related]  

  • 18. Method Development and Application of an Accelerated Solution Stability Screen for Drug Discovery.
    Gomez-Sanchez R; Besley S; Zeliku Z; Young RJ
    SLAS Discov; 2020 Dec; 25(10):1191-1196. PubMed ID: 32522054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Have microfluidics delivered for drug discovery?
    Chandrasekaran A; Abduljawad M; Moraes C
    Expert Opin Drug Discov; 2016 Aug; 11(8):745-8. PubMed ID: 27266956
    [No Abstract]   [Full Text] [Related]  

  • 20. The importance of triaging in determining the quality of output from high-throughput screening.
    Jones P; McElroy S; Morrison A; Pannifer A
    Future Med Chem; 2015; 7(14):1847-52. PubMed ID: 26419190
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.